Theravance Biopharma has named former Acorda Therapeutics Chief Business Officer Andrew Hindman as Senior VP and Chief Financial Officer. Hindman, who led Acorda’s acquisition of Inbrija inhaled L-dopa developer Civitas Therapeutics in 2014, also previously served as President and CEO of Tobira Therapeutics and held executive positions at Onyx Pharmaceuticals and Gilead.
In November 2018, the FDA approved Theravance and Mylan’s Yupelri revefenacin inhalation solution for the treatment of COPD. That same month, the company announced that it had initiated a Phase 1 trial of its TD-8236 inhaled JAK inhibitor for the potential treatment of respiratory diseases such as asthma and COPD.
HIndman commented, “Theravance Biopharma has built one of the industry’s most promising portfolios of commercial products and development-stage programs, with a unique focus on organ-selective drugs that offer the potential for localized therapeutic impact without systemic exposure and related toxicities. With these high-value assets positioning the company for near and long-term success, I am excited to join the team and contribute to efforts to maximize shareholder value. I share the company’s commitment to developing medicines that make a difference in the lives of patients and look forward to working to continue the company’s pursuit of this important goal.”
Theravance Biopharma Chairman and CEO Rick Winningham said, “Andrew’s wide-ranging experience across critical functional areas, combined with his strong track record of driving significant value creation at several well-known life science companies, make him a valuable addition to the Theravance Biopharma team. In addition to his impressive professional experience, Andrew’s reputation for high energy and collaboration clearly distinguished him during our CFO search and positions him as an excellent fit for our corporate culture. We’re excited to welcome Andrew to the Theravance Biopharma team and look forward to the key contributions he will make to the company’s ongoing success.”
Read the Theravance Biopharma press release.
